Become A Member

  1. Home
  2. Volume - 6
  3. REVIEW OF POSSIBLE MECHANISMS BY WHICH LOVASTATIN EITHER PROMOTES OR INHIBITS NEW-ONSET DIABETES IN PATIENTS
Article Image
Chukwuma Chinaza Adaobi , Samuel Kofi Amponsah , Rev. Sr. Lucy Dery, HHCJ , Felix Fiavor , Nicholas Agyepong, PhD

REVIEW OF POSSIBLE MECHANISMS BY WHICH LOVASTATIN EITHER PROMOTES OR INHIBITS NEW-ONSET DIABETES IN PATIENTS

This review paper seeks to identify the possible mechanisms lovastatin either promotes or inhibits new-onset diabetes in patients. Diagnosis for new-onset diabetes in adults includes type 2 diabetes, type 1 diabetes, diseases of the exocrine pancreas, drug-induced diabetes, and much rarer causes, such as maturity-onset diabetes of the young (defined as diabetes diagnosed after hospital discharge for patients with no history of diabetes) in patients. Lovastatin is a lipophilic statin that works with the enzyme HMG-CoA reductase to competitively inhibit HMG-CoA conversion to mevalonate (the rate-limiting step in cholesterol synthesis). Several studies have shown that there might be a high chance of getting new-onset diabetes (NOD) with an increase in dose. The cholesterol derived from plasma is capable of promoting inflammation and induce oxidative stress. This also results in reduced insulin secretion. It had been established that Statins generally lead to cholesterol removal. Although statins have a weak but consistent association with NOD, studies analyzed so far do not give conclusive evidence. Moreover, the benefit of statins in dyslipidemia outweighs the risk of Because not all statins have been proven to have a greater hazard ratio for getting NOD, this is a possibility. Although Lovastatin has a minimal effect on developing NOD, further research and evidence is essential to ascertain a definite conclusion.